Shanghai, China · Founded 2018 · In IPO Registration
Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. Tyligand Bioscience is based in Shanghai, China and was founded in 2018. Its last reported valuation was $222 million in Jan 2026. It has raised $111 million.
Last reported valuation
$222.2M
Oct 2026
Priced at
—
Total raised
$110.6M
Last round
—
Cap table — not yet on record
Tyligand Bioscience's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Tyligand Bioscience with a free account
·The complete investor list: 14 names
·Watch Tyligand Bioscience: the Monday email on marks, rounds and moves
